PBH:NYE-Prestige Brand Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 74.38

Change

+0.56 (+0.76)%

Market Cap

N/A

Volume

0.32M

Analyst Target

USD 45.75
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+1.53 (+0.94%)

USD 74.37B
HLN Haleon plc

+0.03 (+0.32%)

USD 44.13B
TAK Takeda Pharmaceutical Co Ltd A..

-0.11 (-0.82%)

USD 42.24B
RDY Dr. Reddy’s Laboratories Ltd..

+0.14 (+0.89%)

USD 13.11B
CTLT Catalent Inc

N/A

USD 11.52B
ELAN Elanco Animal Health

-0.25 (-2.12%)

USD 5.75B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.19 (+2.41%)

USD 3.59B
BHC Bausch Health Companies Inc

-0.02 (-0.25%)

USD 2.75B
CPHI China Pharma Holdings Inc

-0.05 (-18.78%)

USD 3.69M
YCBD cbdMD Inc

N/A

USD 1.96M

ETFs Containing PBH

NDIA Global X Funds 3.47 % 0.00 %

-0.12 (-0.68%)

USD 0.02B
EMC Global X Funds 2.40 % 0.00 %

-0.18 (-0.68%)

USD 0.11B
XST:CA iShares S&P/TSX Capped Co.. 0.00 % 0.61 %

+0.04 (+-0.68%)

CAD 0.27B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.75% 15% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.75% 15% F 6% D-
Trailing 12 Months  
Capital Gain 24.40% 73% C 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.40% 73% C 79% B-
Trailing 5 Years  
Capital Gain 93.65% 93% A 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 93.65% 86% B+ 84% B
Average Annual (5 Year Horizon)  
Capital Gain 18.57% 80% B- 79% B-
Dividend Return 18.57% 80% B- 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 20.82% 73% C 53% F
Risk Adjusted Return 89.17% 100% F 92% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:

There is nothing we particularly dislike